查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992137

核酸治疗药物研发生产机构（CDMO）市场：依治疗药物类型、服务类型、治疗应用及最终用户划分－2026-2032年全球市场预测

Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核酸疗法 CDMO 市场价值将达到 120 亿美元，到 2026 年将成长至 133.6 亿美元，到 2032 年将达到 261.4 亿美元，复合年增长率为 11.76%。

主要市场统计数据
基准年 2025 120亿美元
预计年份：2026年 133.6亿美元
预测年份 2032 261.4亿美元
复合年增长率 (%) 11.76%

在科学和监管需求不断加快的背景下，CDMO 在推动复杂核酸疗法开发方面的战略作用也在不断演变。

核酸疗法的合约开发与生产（CDMO）产业正进入一个技术快速融合、对研发公司和合约合作伙伴的策略重要性日益凸显的阶段。治疗方法、生产平台和监管要求的最新进展，正使CDMO从单纯的供应商转变为对专案进度和临床可行性具有重大影响的策略合作伙伴。随着研发人员不断探索日益复杂的结构，包括修饰寡核苷酸、病毒载体和脂质奈米颗粒製剂，对专业製程知识、严格的品管和高度灵活的生产能力的需求也日益增长。

阐明正在改变核酸治疗领域研究与开发、生产方法、监管预期和伙伴关係模式的多方面颠覆性因素。

核酸疗法正在改变治疗模式，推动研发、生产和商业化领域的一系列变革。技术创新正在模式转移分子设计、生产和测试方式。模组化和连续生产方法正在许多应用中取代传统的间歇式生产，而数位化製程控制和先进的分析技术作为品质系统和製程理解的基础，其重要性日益凸显。这些变革拓宽了合约研发生产机构（CDMO）的能力要求，需要投资于专用设备、即时监控能力和跨领域人才。

本研究评估了 2025 年关税调整将如何重塑核酸疗法整个供应链的采购、供应商认证和营运风险管理。

美国在2025年实施和调整关税，为核酸疗法生产的供应和成本计算增加了新的变数。影响进口原料、特殊试剂和某些生产设备的关税措施迫使製造商和赞助商重新评估筹资策略，并加快认证替代供应商的步伐。因此，采购团队正在加强对供应商韧性和地理多元化的审查，而生产负责人则在评估维持近岸外包、在岸外包和离岸伙伴关係之间的权衡取舍。

从模式、服务类型、应用程式和最终用户细分中获得策略见解，以优化产能投资和伙伴关係结构。

从多个细分维度分析需求和产能，可以全面整体情况。从治疗药物类型来看，DNA疗法和RNA疗法之间的差异对生产流程、分析测试范式和监管环节都产生了显着影响。 RNA疗法通常需要专门的製剂开发技术和低温运输管理，而DNA疗法在上游和下游纯化製程方面则面临着独特的挑战。从服务类型来看，分析测试与品管、生产、包装和分销以及製程开发和最佳化之间的相互作用决定了价值的创造点。提供端到端服务的机构可以缩短週期并减少交接环节，但专业领域的专家在高度技术性的任务和方法论开发中仍然发挥着至关重要的作用。

解读美洲、欧洲、中东和非洲以及亚太地区的区域生态系统、法规结构和能力发展如何影响CDMO的策略定位。

区域趋势持续影响整个CDMO产业的策略决策，每个区域的需求和产能都受到独特因素的影响。在美洲，蓬勃发展的生物技术生态系统、创业投资投资以及集中的后期临床试验项目，推动了对可扩展生产和严格监管合规性的需求。这种环境促使申办方和生产合作伙伴在临床到商业化的过渡计画中密切合作，这要求对符合GMP标准的设施、监管专业知识和供应链韧性进行投资。

了解竞争优势和伙伴关係模式，使 CDMO 能够透过技术深度、整合服务和以客户为中心的业务结构实现差异化。

在核酸治疗生态系统中，各公司之间的竞争格局日益取决于其在治疗模式方面的专业知识深度、整合式服务交付能力，以及透过已建立的监管合作关係降低从临床试验到实用化风险的能力。主要企业正透过投资平台技术来提升自身竞争力，这些技术能够加快製程开发速度、提高产品品质并实现更有效率的规模化生产。产能本身已不再是决定性因素。相反，那些能够将完善的品质系统、先进的分析技术以及成功的技术转移经验相结合的企业，正享有竞争优势。

高阶主管可采取的策略挑战，以加强伙伴关係、供应链韧性、数位化品质和人才队伍建设，从而开发高可靠性的核酸疗法

行业领导者和专案发起人需要采取一系列切实可行的措施，使其营运、伙伴关係和投资计划与核酸疗法开发不断变化的实际情况相适应。首先，他们应优先考虑共同开发框架，以规范发起人和生产商之间的早期合作，从而加速製程转移并最大限度地减少下游环节的意外事件。设定共同的里程碑和决策节点有助于明确预期，并减少规模化生产过程中的返工。其次，他们应投资于供应链透明度和关键原料及合格试剂的双重采购策略，以因应贸易政策波动和单一来源依赖的风险。儘早对供应商进行资格认证，可以在需要寻找替代供应商时缩短时间。

本文描述了一种混合方法研究设计，该设计结合了对专家的初步访谈、技术检验和三角验证的二级资讯来源，以确保研究结果的可行性和合理性。

本研究采用的调查方法整合了多种证据来源，以确保获得可靠且可操作的见解。辅助研究包括对科学文献、监管指导文件、行业白皮书和技术标准进行系统性回顾，以建立技术和监管基准。主要研究则对製造经理、製程科学家、监管专家、采购经理和专案经理进行了结构化访谈，以收集关于营运挑战、供应商绩效和伙伴关係动态的第一手观点。这些质性资讯辅以技术检验工作，包括近期技术转移案例研究分析、可比性研究和製程放大实例。

本文整合了能力、伙伴关係和供应链韧性的策略协调如何决定核酸疗法从发现到供应的成功部署。

在科学创新、不断变化的监管预期和营运需求的驱动下，核酸疗法的生产格局瞬息万变。那些认识到CDMO（合约研发生产机构）伙伴关係的战略意义，并投资于分析卓越性、适应性生产和弹性供应链等综合能力的企业，将更有能力将科学进展转化为可靠的临床和商业供应。关税导致的供应调整、区域生产能力的重组以及对先进分析的需求等转型挑战，虽然会带来营运上的困难，但也为那些能够检验清晰且经过验证的、风险可控的规模化生产路径的供应商创造了新的机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：核酸治疗药物－依治疗药物类型分類的CDMO市场

  • DNA治疗药物
  • RNA疗法

第九章：核酸治疗药物研发生产机构（CDMO）市场：依服务类型划分

  • 分析测试和品管
  • 製造业
  • 包装/配送
  • 製程开发与最佳化

第十章：核酸治疗药物CDMO市场（依治疗应用划分）

  • 遗传性疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学
  • 罕见疾病

第十一章：核酸治疗药物研发生产力机构（CDMO）市场：依最终用户划分

  • 学术和研究机构
  • 生技公司
  • 製药公司

第十二章：核酸治疗药物研发生产机构（CDMO）市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：核酸治疗药物研发生产机构（CDMO）市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：核酸治疗药物研发生产力机构（CDMO）市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国核酸治疗药物和CDMO市场

第十六章：中国核酸治疗药物CDMO市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • The Scripps Research Institute
  • Touchlight Group
  • Univercells Group
  • WuXi AppTec Co., Ltd.
Product Code: MRR-CA7E340319CD

The Nucleic Acid Therapeutics CDMO Market was valued at USD 12.00 billion in 2025 and is projected to grow to USD 13.36 billion in 2026, with a CAGR of 11.76%, reaching USD 26.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.00 billion
Estimated Year [2026] USD 13.36 billion
Forecast Year [2032] USD 26.14 billion
CAGR (%) 11.76%

Framing the evolving strategic role of CDMOs in enabling complex nucleic acid therapeutic development amid accelerating scientific and regulatory demands

The nucleic acid therapeutics contract development and manufacturing landscape has entered a phase defined by rapid technological convergence and elevated strategic importance for both developers and contract partners. Recent advances in therapeutic modalities, manufacturing platforms, and regulatory expectations have elevated CDMOs from service vendors to strategic collaborators that materially influence program timelines and clinical viability. As developers pursue increasingly complex constructs, including modified oligonucleotides, viral vectors, and lipid nanoparticle formulations, demand for specialized process knowledge, stringent quality control, and adaptive manufacturing capacity has intensified.

Consequently, organizations that provide integrated capabilities spanning process development, analytical rigor, and scale-ready manufacturing are being evaluated not only on cost and capacity but also on agility, regulatory track record, and partnership models that de-risk development pathways. Stakeholders must therefore reassess their sourcing strategies, technology roadmaps, and compliance frameworks to reflect an environment where speed-to-clinic and supply continuity are as critical as technical excellence. Moving forward, the interplay between scientific innovation and pragmatic manufacturing constraints will determine which programs advance efficiently and which face protracted development timelines, making it imperative for executives to align commercial strategy with operational realities across the value chain.

Unpacking the multidimensional disruptive forces altering R&D, manufacturing modalities, regulatory expectations, and partnership models across nucleic acid therapeutics

Nucleic acid therapeutics are reshaping therapeutic paradigms, and with that transformation comes a cascade of shifts across R&D, manufacturing, and commercialization. Technological innovation is driving paradigm changes in how molecules are designed, produced, and tested; modular and continuous manufacturing approaches are replacing batch orthodoxy in many applications, while digital process controls and advanced analytics increasingly underpin quality systems and process understanding. These shifts have broadened the competency set required of contract development and manufacturing organizations, requiring investments in specialized equipment, real-time monitoring capabilities, and cross-disciplinary talent.

At the same time, regulatory expectations have matured, emphasizing lifecycle quality management, data integrity, and platform-based comparability. This maturation is influencing project planning and capitalization decisions and is prompting greater early-stage alignment between developers and manufacturers on quality by design principles. Moreover, commercial pressures are altering partnership structures: strategic alliances, risk-sharing arrangements, and capacity reservation models are becoming more common as sponsors seek to secure prioritized throughput and mitigate supply chain risk. Taken together, these transformative shifts mean that CDMOs must evolve beyond transactional relationships to become long-term strategic partners that co-design processes, anticipate regulatory challenges, and scale capabilities in lockstep with evolving modality requirements.

Assessing how tariff adjustments in 2025 have recalibrated sourcing, supplier qualification, and operational risk management across the nucleic acid therapeutics supply chain

The imposition and adjustment of tariffs by the United States in 2025 have introduced new variables into the supply and cost calculus for nucleic acid therapeutics manufacturing. Tariff measures that affect imported raw materials, specialized reagents, and certain manufacturing equipment have prompted manufacturers and sponsors to reassess sourcing strategies and to accelerate efforts to qualify alternative suppliers. As a result, procurement teams have increased scrutiny of supplier resilience and geographic diversification while manufacturing planners evaluate the trade-offs between nearshoring, onshoring, and maintaining offshore partnerships.

In practice, these tariff-driven dynamics have influenced capital allocation decisions and timetable assumptions. Sponsors that previously relied on a global sourcing model for key inputs have initiated dual-sourcing strategies and have elevated buffer management to preserve continuity for critical campaigns. Investments in supplier qualification and audits have increased, as firms seek to validate localized supply chains. Moreover, some organizations have advanced plans for regional capacity expansion to reduce exposure to cross-border cost volatility and mitigate potential lead-time disruptions. Regulatory dossiers and quality control frameworks have had to accommodate the introduction of new supplier-origin materials, requiring targeted comparability studies and additional documentation. While tariffs have not altered the scientific principles behind modality development, they have reshaped operational risk management and have heightened the strategic importance of supply chain transparency, supplier performance metrics, and contractual protections that address cross-border trade risk.

Deriving strategic implications from modality, service type, application, and end-user segmentation to target capability investments and partnership structures

A granular view of the landscape emerges when analyzing demand and capability along multiple segmentation axes. When viewed through the lens of therapeutic type, distinctions between DNA therapeutics and RNA therapeutics materially influence manufacturing workflows, analytical testing paradigms, and regulatory touchpoints; RNA modalities often demand specialized formulation expertise and cold-chain considerations, while DNA-based approaches entail distinct upstream and downstream purification challenges. From the perspective of service type, the interplay between analytical testing and quality control, manufacturing, packaging and distribution, and process development and optimization defines where value accrues; organizations that integrate end-to-end services can shorten timelines and reduce handoffs, while niche specialists retain relevance for highly technical tasks and method development.

Considering therapeutic application highlights divergent demand drivers: genetic disorders, infectious diseases, neurological disorders, oncology, and rare disorders each present unique payload requirements, dosing regimens, and clinical development risk profiles, which in turn shape manufacturing complexity and demand for tailored assays. Finally, end-user segmentation-academic and research institutes, biotechnology firms, and pharmaceutical companies-reveals differing expectations for flexibility, timelines, and regulatory support; academic partners often require adaptable, lower-volume services focused on method establishment, biotechnology firms prioritize speed and platform scalability for clinical progression, and pharmaceutical companies seek predictable quality systems and capacity for late-stage scale-up. Integrating these segmentation perspectives provides a multidimensional map to prioritize investments, align service offerings, and design partnership models that reflect client-specific needs and modality attributes.

Interpreting how regional ecosystems, regulatory frameworks, and capacity development across the Americas, EMEA, and Asia-Pacific shape CDMO strategic positioning

Regional dynamics continue to influence strategic decisions across the CDMO landscape, with distinct drivers shaping demand and capability in each geography. In the Americas, robust biotech ecosystems, venture capital activity, and a concentration of late-stage clinical programs drive demand for scalable manufacturing and stringent regulatory compliance. This environment fosters closer collaboration between sponsors and manufacturing partners on clinical-to-commercial transition planning and necessitates investments in GMP-capable facilities, regulatory affairs expertise, and supply chain resilience.

In Europe, the Middle East & Africa, evolving regulatory harmonization efforts, a strong translational research base, and growing local biomanufacturing initiatives create opportunities for regional partners to offer specialized capabilities and navigate complex cross-border regulatory landscapes. Sponsors operating in these jurisdictions often balance access to localized scientific talent with the need for interoperable quality systems and regulatory dossiers that align with multiple authorities. The Asia-Pacific region is characterized by rapid capacity expansion, a maturing supplier base for reagents and components, and significant investments by governments and private entities to build domestic manufacturing capabilities. This has encouraged the development of cost-effective manufacturing options as well as opportunities for technology transfer and joint ventures. Across all regions, supply chain transparency, compliance consistency, and the ability to execute complex analytics remain critical selection criteria for sponsors seeking to mitigate geopolitical and operational risks.

Understanding the competitive levers and partnership models that enable CDMOs to differentiate through technical depth, integrated services, and customer-aligned commercial structures

Competitive dynamics among companies serving the nucleic acid therapeutics ecosystem are increasingly defined by depth of modality expertise, integrated service offerings, and the ability to de-risk clinical translation through proven regulatory engagement. Leading providers distinguish themselves by investing in platform technologies that enable faster process development, higher product quality, and streamlined scale-up pathways. Capacity alone no longer differentiates; rather, organizations that combine robust quality systems with advanced analytics and a track record of successful transfers enjoy a competitive edge.

Partnership models are evolving: strategic alliances, co-development agreements, and capacity reservation arrangements are common among organizations seeking to secure long-term pipeline throughput. Investment in talent-particularly in process scientists, analytical chemists, and regulatory specialists-is a critical differentiator, as is the ability to demonstrate successful comparability and validation work across multiple modalities. Mergers and acquisitions continue to be a lever for accessing niche capabilities quickly, but the integration of disparate quality systems and cultures requires deliberate planning. Finally, forward-looking companies prioritize customer-centric commercial models that offer transparency around capacity, pricing mechanisms that reflect value and risk, and collaborative governance structures to resolve program-level challenges efficiently.

Actionable strategic imperatives for executive leaders to strengthen partnerships, supply resilience, digital quality, and talent for reliable nucleic acid therapeutic development

Industry leaders and program sponsors must adopt a set of pragmatic actions to align operations, partnerships, and investment plans with the evolving realities of nucleic acid therapeutic development. First, prioritize co-development frameworks that formalize early-stage collaboration between sponsors and manufacturers to accelerate process transfer and minimize downstream surprises. Establishing joint milestones and decision gates clarifies expectations and reduces rework during scale-up. Second, invest in supply chain visibility and dual-sourcing strategies for critical raw materials and specialized reagents to manage exposure to trade policy shifts and single-source dependencies. Engaging in supplier qualification early will shorten timelines when alternate sources are needed.

Third, accelerate adoption of digital quality management and process analytical technologies to enable real-time monitoring and to support regulatory dossiers that emphasize lifecycle control. These investments reduce batch failure risk and enhance comparability assessments across manufacturing sites. Fourth, align commercial agreements with operational realities by incorporating capacity reservation clauses, risk-sharing provisions, and transparent escalation mechanisms for schedule adjustments. Fifth, build internal capabilities through targeted hiring and training programs that focus on analytics, aseptic processing, and regulatory strategy, while also evaluating strategic acquisitions or partnerships to fill capability gaps rapidly. By implementing these measures, organizations can reduce program risk, preserve development momentum, and create clearer pathways from discovery to commercial supply.

Explaining the mixed-methods research design combining primary expert interviews, technical validation, and triangulated secondary sources to ensure actionable and defensible insights

The underlying research methodology synthesizes multiple evidence streams to ensure robust, actionable insights. Secondary research involved systematic review of scientific literature, regulatory guidance documents, industry white papers, and technical standards to establish baseline technical and regulatory contexts. Primary research consisted of structured interviews with manufacturing leaders, process scientists, regulatory experts, procurement leads, and program managers to capture first-hand perspectives on operational challenges, supplier performance, and partnership dynamics. These qualitative inputs were complemented by technical validation exercises, including case study analyses of recent technology transfers, comparability efforts, and process scale-up examples.

Data triangulation was applied to corroborate themes across sources, ensuring that observed patterns in capacity expansion, quality system investments, and supply chain strategies were not isolated anecdotes. The methodology also incorporated scenario analysis to evaluate the operational implications of shifts such as tariff changes, regional capacity additions, and modality-specific manufacturing complexities. Where appropriate, the research team validated assumptions through follow-up interviews and document reviews to minimize bias. Together, these methods yield a defensible synthesis that balances technical specificity with strategic relevance for decision-makers in development, manufacturing, and commercial organizations.

Synthesizing how strategic alignment of capabilities, partnerships, and supply chain resilience determines successful translation of nucleic acid therapeutics from discovery to supply

The landscape for nucleic acid therapeutics manufacturing is in flux, driven by scientific innovation, evolving regulatory expectations, and shifting operational imperatives. Organizations that recognize the strategic nature of CDMO partnerships and that invest in integrated capabilities-spanning analytical excellence, adaptive manufacturing, and resilient supply chains-will be better positioned to convert scientific advances into reliable clinical and commercial supply. Transitional pains such as tariff-driven supply adjustments, regional capacity realignment, and the need for advanced analytics present operational challenges, but they also create opportunities for providers that can offer clear, validated pathways to de-risked scale-up.

Ultimately, success will favor those who approach manufacturing as a strategic asset rather than a transactional function, establishing collaborative governance, transparent commercial terms, and continuous improvement processes that accelerate program timelines and reduce technical and regulatory risk. By aligning investment priorities with modality-specific demands and by cultivating flexible, high-integrity supply chains, sponsors and providers can create more predictable development trajectories and realize the full potential of nucleic acid therapeutics across diverse therapeutic areas.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type

  • 8.1. DNA Therapeutics
  • 8.2. RNA Therapeutics

9. Nucleic Acid Therapeutics CDMO Market, by Service Type

  • 9.1. Analytical Testing & Quality Control
  • 9.2. Manufacturing
  • 9.3. Packaging & Distribution
  • 9.4. Process Development & Optimization

10. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications

  • 10.1. Genetic Disorders
  • 10.2. Infectious Diseases
  • 10.3. Neurological Disorders
  • 10.4. Oncology
  • 10.5. Rare Disorders

11. Nucleic Acid Therapeutics CDMO Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Biotechnology Firms
  • 11.3. Pharmaceutical Companies

12. Nucleic Acid Therapeutics CDMO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nucleic Acid Therapeutics CDMO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nucleic Acid Therapeutics CDMO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nucleic Acid Therapeutics CDMO Market

16. China Nucleic Acid Therapeutics CDMO Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AGC Biologics Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Ajinomoto Bio-Pharma Services
  • 17.8. Almac Group Ltd.
  • 17.9. Biomay AG
  • 17.10. BioSpring GmbH
  • 17.11. Catalent, Inc.
  • 17.12. Charles River Laboratories International, Inc.
  • 17.13. CordenPharma International GmbH
  • 17.14. Creative Biogene
  • 17.15. Danaher Corporation
  • 17.16. Eurofins Scientific SE
  • 17.17. Evonik Industries AG
  • 17.18. GenScript Biotech Corporation
  • 17.19. Lonza Group Ltd.
  • 17.20. Polypeptide Group AG
  • 17.21. Recipharm AB
  • 17.22. Rentschler Biopharma SE
  • 17.23. Samsung Biologics
  • 17.24. The Scripps Research Institute
  • 17.25. Touchlight Group
  • 17.26. Univercells Group
  • 17.27. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 99. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 119. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)